A Randomized, Single-blind, Controlled Clinical Study of Cardiomyopeptidin on Improving Ischemia-reperfusion Injury in Patients With Acute ST-segment Elevation Myocardial Infarction After Primary PCI - Trial NCT06155110
Access comprehensive clinical trial information for NCT06155110 through Pure Global AI's free database. This Phase 4 trial is sponsored by Chinese PLA General Hospital and is currently Recruitment Completed. The study focuses on Cardiovascular Diseases. Target enrollment is 160 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Chinese PLA General Hospital
Timeline & Enrollment
Phase 4
Mar 01, 2022
May 01, 2024
Primary Outcome
Myocardial infarct size according to MR delayed enhancement scan
Summary
This study aim to investigate the myocardium protection effect of cardiomyopeptidin in
 patients undergoing primary PCI for ST-elevation myocardial infarction through myocardial
 enhanced MRI.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06155110
Non-Device Trial